Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

198 trials with published results (24%)

Research Maturity

666 completed trials (80% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

5.1%

43 terminated out of 835 trials

Success Rate

93.9%

+7.4% vs benchmark

Late-Stage Pipeline

36%

304 trials in Phase 3/4

Results Transparency

30%

198 of 666 completed with results

Key Signals

198 with results94% success43 terminated

Data Visualizations

Phase Distribution

714Total
Not Applicable (223)
Early P 1 (6)
P 1 (73)
P 2 (108)
P 3 (193)
P 4 (111)

Trial Status

Completed666
Unknown58
Terminated43
Recruiting22
Not Yet Recruiting16
Withdrawn12

Trial Success Rate

93.9%

Benchmark: 86.5%

Based on 666 completed trials

Clinical Trials (835)

Showing 20 of 20 trials
NCT05362903CompletedPrimary

A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

NCT07406191Not ApplicableRecruiting

WB-EMS Effects on Cardiometabolic Risk Factors

NCT05192941Phase 4CompletedPrimary

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

NCT07524101Not ApplicableNot Yet Recruiting

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

NCT06568601Not ApplicableRecruitingPrimary

Pharmacogenomic Informed Statin Prescribing

NCT07175766Not ApplicableCompleted

Dachundou No Sugar Added Soymilk for Lipid Modulation

NCT07514663Not ApplicableRecruitingPrimary

Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile

NCT07508254Phase 4Not Yet Recruiting

Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome

NCT06112327Enrolling By Invitation

Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease

NCT00353782RecruitingPrimary

Causes and Natural History of Dyslipidemias

NCT06450366Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

NCT07489183CompletedPrimary

A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older

NCT04579367Active Not RecruitingPrimary

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

NCT06301906CompletedPrimary

Red Yeast Rice for Primary Prevention of Hypercholesterolemia

NCT07474649Phase 3Not Yet Recruiting

A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

NCT06304415Active Not RecruitingPrimary

Elevated Lipoprotein(a) in Hospital Staff

NCT07477704Phase 2Not Yet RecruitingPrimary

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT07382414Not ApplicableNot Yet Recruiting

Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial

NCT00001154Completed

Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

NCT07447206Phase 2Not Yet Recruiting

Vascular Intervention Strategies Trial for Alzheimer's

Scroll to load more

Research Network

Activity Timeline